Development of In Vitro Diagnostics for the Detection of SARS-CoV-2

开发用于检测 SARS-CoV-2 的体外诊断方法

• 批准号: 10912989
• 负责人: SCOTT SCHAUS
• 金额: $ 459.09万
• 依托单位: SORRENTO THERAPEUTICS, INC.
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-06-01 至 2025-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10912989
• 关键词: Area; Blood; COVID-19 detection; COVID-19 diagnostic; Coronavirus; Detection; Development; Emerging Communicable Diseases; Infection; Methods; Nucleic acid sequencing; Performance; Proteins; Toxin; biothreat; diagnostic technologies; improved; in-vitro diagnostics; microbial; pathogen

To support the development of promising diagnostics technologies for biothreat pathogens and toxins, as well as pathogens causing emerging and reemerging infectious diseases. Areas of support may focus on improving performance of agnostic nucleic acid sequencing solutions on commercial platforms; methods that improve protein analyte detection; and efforts to improve direct-from-blood or other biofluid detection and identification of microbial infection.

支持开发有希望的生物治疗病原体和毒素的诊断技术，以及导致新兴和重新出现感染性疾病的病原体。支持领域可能会集中于提高商业平台上不可知的核酸测序溶液的性能；改善蛋白质分析物检测的方法；并努力改善直接流血或其他生物流体检测和微生物感染的鉴定。